Gensight Biologics
Clinical trials sponsored by Gensight Biologics, explained in plain language.
-
Gene therapy tested in single patient with rare blindness condition
Disease control NO_LONGER_AVAILABLEThis expanded access program allowed one patient with Leber Hereditary Optic Neuropathy (a genetic condition causing vision loss) to receive GS010 gene therapy via injections into both eyes. The goal was to assess safety, not to cure the disease. The study is no longer available.
Sponsor: GenSight Biologics • Aim: Disease control
Last updated May 26, 2026 11:08 UTC
-
Gene therapy and light glasses offer new hope for rare blindness
Disease control OngoingThis study tests a gene therapy injection followed by wearing light-stimulating glasses for people with retinitis pigmentosa, a rare eye disease that causes vision loss. The goal is to see if the treatment is safe and can improve vision. Ten adults aged 18 to 75 with advanced vis…
Phase: PHASE1, PHASE2 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated May 20, 2026 12:08 UTC